Skip to content

PTSD: all studies

Page 100 of 210: studies 991 to 1,000 of 2,096, newest first. Back to the PTSD overview

Research

Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations

Expert Opinion on Pharmacotherapy March 24, 2026 Donatella Marazziti, Matteo Gambini, Riccardo Gurrieri et al.

INTRODUCTION: After decades of regulatory marginalization, psychedelic compounds have reemerged as promising therapeutic tools in psychiatry, driven by unmet clinical needs in treatment-resistant mental disorders and by growing evidence of rapid and sustained effects on mood, cognition, and behavior. AREAS COVERED: This narrative review critically examined the current clinical and regulatory...

DOI: 10.1080/14656566.2026.2654682 (opens in new tab) Clinical trial Medical prescription Medline Equity law +4

Traumer og ånder efter krig i Uganda: Konfigurationer af vold og behandling

Tidsskrift for Forskning i Sygdom og Samfund March 20, 2026 Lars Hedegaard Williams, Lotte Meinert 2 citations

I kølvandet på 20 års borgerkrig i det nordlige Uganda fulgte en bølge af traumer, onde ånder og vold, som fortsat forpester livet og fordrer handling. Brutaliteten og de mange ubegravede lig som krigen efterlod, opleves af mange som årsag til forskellige former for åndelig og social kontaminering. I en biomedicinsk forståelse beskrives forstyrrelserne som Post Traumatisk Stress Syndrom (PTSD),...

Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.

Journal of Psychoactive Drugs March 20, 2026 Marina A. M. Portes, Leandro J Bertoglio

Psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) are psychedelic compounds with therapeutic potential for depression, anxiety, and post-traumatic stress. However, their relevance to endurance athletes, who face particular psychological and physical stressors, remains underexplored. This study combines a conceptual overview...

O potencial terapêutico dos psicodélicos no tratamento de distúrbios neuropsiquiátricos

OUTRAS PALAVRAS March 18, 2026 Gabriela Marques Guimarães Simão, Isabella Andrade Santana, Luiza Paulone Santos Fortunato Dias et al.

O presente estudo aborda o potencial terapêutico dos psicodélicos no tratamento de distúrbios neuropsiquiátricos, destacando sua relevância em um contexto de crescente prevalência de condições como depressão, ansiedade e transtorno de estresse pós-traumático. O objetivo principal é investigar as propriedades farmacológicas desses compostos, seus mecanismos de ação e os resultados clínicos...

DOI: 10.54899/rop.v23n1-2592 (opens in new tab) Anxiety Context archaeology Limiting Work physics +1

A conceptual metacognitive mindfulness model for enhancing resilience and mental well-being among firefighters

Discover Public Health March 17, 2026 Albin Joseph, Tony Jose

Firefighters face significant inherent risks which leads to an increase in mental health problems such as post-traumatic stress disorder (PTSD), anxiety, and depression. The mental health challenges have negative impacts both on their personal health and their professional performance which results in higher staff turnover rates. This research proposes an innovative conceptual framework that...

Yoga in Managing Psychiatric Disorders

International Journal of Advanced Research in Science, Communication and Technology March 17, 2026 Gajanan Tekale Pornima Gautam Surwade, Dr. Shivshankar D. Mahske

Yoga, an ancient mind-body practice originating from India, has gained recognition as a complementary intervention for managing psychiatric disorders. Derived from the Sanskrit term “Yuj,” meaning “to unite,” yoga integrates physical postures (asanas), breath regulation (pranayama), and meditation (dhyana) to promote harmony between body, mind, and spirit. Unlike conventional exercise, yoga...

Editorial: Psychedelic substances and neurological diseases: from basics to clinical application

Frontiers in Pharmacology March 16, 2026 Alessandra Linardi, Ariadiny Lima Caetano, Rodrigo Portes Ureshino

psychiatric disorders, beta-carbolines, trace amine, phosphoproteomics, social hierarchy. Scientific interest in psychedelic substances has re-emerged, offering new perspectives on the treatment of neuropsychiatric and neurological disorders.Historically, psychedelics have been associated with a wide spectrum of positive and negative effects, encompassing ritualistic and spiritual use,...

DOI: 10.3389/fphar.2026.1816812 (opens in new tab) Addiction Neurotoxicity Mechanism biology Recreational use +7

The renaissance of research on psychedelics in child and adolescent psychopharmacology

Child and Adolescent Psychiatry and Mental Health March 13, 2026 Marc-Antoine Crocq, Philippe Auby

Aims The recent regulatory approval of esketamine in adults heralded the renaissance of research into psychedelic compounds. However, the relevance of this resurgence for children and adolescents remains unclear. This review examines the rationale for investigating psychedelics in pediatric psychopharmacology. Methods We reviewed recent literature, regulatory documents, and clinical trial...

TERAPIAS EMERGENTES COM PSICOTRÓPICOS EM TRANSTORNOS PSIQUIÁTRICOS

Editora Pasteur eBooks March 11, 2026 Ana Carolina Baldi Pasqualini, Henrique Wojciechowski Osorio, Veridiana Powarczuk et al.

Introdução: Os transtornos psiquiátricos representam um importante desafio na saúde pública mundial, com impacto significativo na qualidade de vida, funcionalidade e mortalidade dos pacientes. Embora os psicofármacos tradicionais, como antidepressivos, antipsicóticos e estabilizadores de humor sejam amplamente utilizados, muitos indivíduos apresentam resposta insatisfatória, falha terapêutica...

Strategic Neurodelivery of Psychedelic Compounds: Bridging Molecular Pharmacology with Therapeutic Innovation in CNS Disorders.

CNS & Neurological Disorders - Drug Targets March 11, 2026 Shikha Baghel Chauhan, Naziya Akhtar, Chirag Jain et al.

Psychedelic compounds such as psilocybin, Lysergic Acid Diethylamide (LSD), N,Ndimethyltryptamine (DMT), and 3,4-methylenedioxymethamphetamine (MDMA) are emerging as novel therapeutics for neuropsychiatric disorders, including depression, Post-Traumatic Stress Disorder (PTSD), and addiction. Acting primarily through serotonin 5-HT2A receptor agonism, they activate intracellular cascades...